Stay updated on Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Sign up to get notified when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.

Latest updates to the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal regarding a Phase II clinical trial for high-risk Multiple Myeloma, including detailed descriptions of the study's objectives, inclusion and exclusion criteria, and investigational details. The only notable addition is a reference to the study's revision number.SummaryDifference20%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
Stay in the know with updates to Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.